A major systematic review led by researchers at Oregon Health & Science University (OHSU) has concluded that certain cannabis products are approximately as effective as ibuprofen for managing chronic pain. However, the findings come with a significant caveat: the pain-relieving benefits are primarily driven by tetrahydrocannabinol (THC), not CBD.
The review, published in the Annals of Internal Medicine, analyzed data from 25 randomized controlled trials conducted across the United States, Canada, and Europe. The research team found that while cannabis can reduce chronic pain, the overall improvement is modest—typically lowering pain levels by about 1 point on a 10-point scale. Notably, this level of relief is statistically similar to that provided by conventional painkillers, including ibuprofen and opioids.
THC vs. CBD: What Actually Works?
For advocates of medical cannabis, the results present a mixed bag. While the study validates the efficacy of cannabis as a pain management tool, it challenges the popular narrative surrounding CBD (cannabidiol) — our cannabidiol guide covers what the compound actually does. The review determined that products containing only CBD had a “trivial effect” on pain reduction in these specific trials.
This contrasts with other emerging research looking into specific applications, such as the potential of high-dose CBD for post-surgical pain, suggesting that dosage and specific medical contexts play critical roles.
Roger Chou, a professor and pain management specialist at OHSU who led the study, highlighted the discrepancy between marketing and clinical reality. “The idea or hope has been that the CBD component might be the one that provides the therapeutic effects,” Chou stated. “Unfortunately, what we found was that the CBD products essentially had no impact on pain.”
A Global Perspective on Pain Management
The study analyzed trials from multiple countries, highlighting the growing global interest in cannabinoid science. As research expands—from these clinical trials in the Northern Hemisphere to population studies on cannabis use in Brazil—the medical community is gaining a clearer picture of how these compounds affect different populations.
The OHSU review suggests that to achieve pain relief, patients may need to utilize products with significant amounts of THC. However, this increases the likelihood of side effects such as sedation, dizziness, and nausea.
Despite the clinical data, Dr. Chou urges caution in interpreting the results too rigidly for individual patients. He noted that studies measure average responses, and individual experiences can vary widely. “I don’t think our study says anything that would say you have to stop your CBD,” Chou said, encouraging patients who currently find relief through CBD to continue their regimen if it works for them.
The review underscores a broader issue in pain management: most current treatments often fall short of completely eliminating chronic pain. As the medical community continues to search for safer alternatives to opioids, understanding the specific roles of cannabinoids remains a critical priority for doctors and patients alike.
